Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease.

ABSTRACT:

Background and objective

Among patients with chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM) is a common comorbidity and is probably associated with increased systemic inflammation and worse prognosis. Metformin, with its pleiotropic anti-inflammatory and antioxidant actions, may offer theoretical benefits in COPD patients with DM. Thus, this study aimed to investigate the effects of DM and metformin use on mortality in the clinical trajectory of COPD.

Methods

This was a retrospective cohort study comprising patients with spirometry-confirmed COPD and an age of ≥40 years from 2008 to 2014. The primary outcome of interest was all-cause mortality. We evaluated the effects of DM on mortality through the clinical course of COPD and we also assessed the impac

SUBMITTER: Ho TW 

PROVIDER: S-EPMC6451256 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature